Web Analytics

Brenda Maloney Shafer, Richard Davis and David Blank’s Article Showcased in Pratt’s Government Contracting Law Report

Media Mention
Pratt’s Government Contracting Law Report

Many drug manufacturers have decided that the Health Resources and Services Administration’s Office of Pharmacy Affairs guidance on contract pharmacy encounters are causing significant disruption in operations and generating a loss of revenue for all types of 340B covered entities. In this issue of Pratt’s Government Contracting Law Report, Brenda Maloney Shafer, Richard Davis and David Blank elaborate on this problem and discuss how it is required for manufacturers to offer 340B pricing on appropriate drugs dispensed by contract pharmacies.

Follow Quarles

Subscribe Media Contact
Back to Main Content

We use cookies to provide you with the best user experience on our website and to analyze statistics related to our website. To understand more about how we use cookies, or for instructions to change your preference and browser settings, please see our Privacy Notice. Please note that if you choose to reject cookies, doing so may impair some of our website's functionality.